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Summary
The specificity of binding of solubilized, purified HLA-A,B molecules to solid-phase peptides
has been examined using the assay described by Bouillet et al. [1989 . Nature (Lon4 339:473 .]
64 peptides derived from the sequences of viral antigens, HLAA,B,C heavy chains, and clathrin
light chains were tested for binding to HLAA2.1, Aw68.1, Aw69, B44, and B5, molecules that
differ by 5-17 residues of the peptide binding groove . 15 of the peptides, including those known
to be T cell epitopes, gave significant binding. The pattern of peptide binding for each of the
fiveHLA-A,B molecules was not significantly different . Binding was demonstrated to be a property
of native 02m-associated HLAA,B molecules that preserved conformational antigenic deter-
minants after binding to peptide. In comparison to our previous results from solution-based
assays the proportion of HLAA,B molecules that can bind solid-phase peptides is very high.
This accessibility of solid-phase peptides to the binding site ofMHC molecules may be directly
related to the observed absence ofMHC specificity in the binding .
Study of T cells has shown that their antigen receptors
(TCR) recognize a specific combination ofMHC mole-
cule andbound peptide (1-3) . Crystallographic structures for
HLAA2.1 and HLAAw68.1 revealed the antigen recogni-
tion site (4, 5) and sequence comparisons showed that residues
lining this groove are the foci for diversity in MHC mole-
cules (6) . Moreover, the substitutions at these positions are
clearly the result ofpositive evolutionary selection (7-9) . In
general it has been reasoned that substitutions within the
groove serve to affect the peptides bound by MHC mole-
cules, a concept supported by the observed differences in the
pockets of the peptide binding grooves of HLAA2.1 and
HLA-Aw68.1 and in the shape of the "extra" material they
contain (4, 5, 10) . That each individual uses a small number
(3-6) of class I molecules to present numerous peptides to
a diversity ofTCR necessitates that eachMHC molecule binds
many peptides and engages many TCR . Thus, there are ar-
guments supporting both specificity and degeneracy in MHC-
peptide interactions. For class IMHC molecules experimental
definition of the specificity of the binding site has proved
difficult. This is due to the presence of tightly bound pep-
tides in isolated class I molecules and uncertainty as to the
relevance of experimental assays to the mechanism ofpeptide
binding in vivo.
Previously we demonstrated binding of radio-iodinated
influenza peptides to solubilized class I HLA molecules in
a manner that correlated with the pattern ofMHC restric-
tion (11) . We also obtained some evidence for the binding
of peptides to nonpresenting MHC molecules . In these
solution-based assays the proportion ofclass I molecules with
accessible peptide binding sites was exceedingly low (<1 in
300), a property that significantly limits their applications .
Bouillot and colleagues have developed a different assay, in
which the binding of radio-iodinated class I HLA molecules
to solid-phase peptides is measured (12) . Binding was more
readily detected than in the solution assay and though dis-
cerning quantitative differences in binding, Bouillot et al . (12)
concluded that "Peptides which are recognized by cytotoxic
T lymphocytes bind not only to the restricting MHC class
I molecule but also to other class I molecules:' A striking
difference in results obtained with the solid-phase assay com-
pared with those obtained with the solution assay was that
up to -25% of the radio-iodinated class I molecules were
capable of binding to experimentally offered peptides. This
property and the capacity to rapidly screen large numbers
of peptides give the solid-phase assay potential for wide ap-
plications in the analysis ofpeptide binding to class IMHC
molecules. Here we compare the binding of 5 class I HLA
molecules to 64 peptides .
Materials and Methods
Peptides.
￿
Peptides were synthesized by a solid-phase method
using FMOC or tBOC chemistry. Homogeneity of the peptides
was indicated by reverse-phase HPLC.
Isolation ofHLA Molecules.
￿
HLA molecules were purified from
detergent solubiliwd cell lysates by immunoaffinity chromatography
as previously described (13). HLAA2.1, Aw69,and Aw68 .1 mole-
cules were purified from cell lysates of human lymphoblastoid
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Volume 172 September 1990 931-936B cell lines 721.53 (A2), IDF (Aw69, A26, B18, Bw38), and
CIR.Aw68 .1 (a HLA-A,B-negative cell line transfected with the
Aw68 .1 gene), respectively, using a monoclonal antiA2, Aw69,Aw68
(CR11.351) antibody column . HLA-B5 and B44 molecules were
purified from cell lysates ofB-lymphoblastoid cell line 721.144 (B5)
and C1R.B44 (a B44 transfectant), respectively, using a mono-
morphic anti-HLA-A,B,C (W6/32) monoclonal antibody column .
Peptide Binding Assay.
￿
Direct binding ofradiolabeledHLA mol-
ecules to peptides precoated onto polystyrene microtiter wells was
as described by Bouillot et al . (12) . Briefly, HLA molecules were
labeled with 1 mCi of I'll (Amersham Corp., Arlington Heights,
IL) by the chloramine T method and fractions containing radiola-
beledHLA molecules were collected from a Sephadex G50 column .
The HLA molecules were diluted in PBS containing 0.5% (NP-
40), 1% BSA, 0.02% NaN3, and 1 mM PMSF. Peptides at 1
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Figure 1 .
￿
Primary amino acid sequences of peptides . Peptides were synthesized on a Milligen/Biosearch 9600 automatic peptide synthesizer
using Fmoc chemistry. 02m = 02 microglobulin; Flu = influenza ; M = matrix protein; NP = nucleoprotein; HIV = human immunodefi-
ciency virus ; LMP = latent membrane protein of Epstein-Barr virus ; LCa, LCb = light chain a and b of clathrin proteins .
mg/ml were plated in duplicates in polystyrene microtiter plates
(Dynatech, Alexandria, VA) . Plates containing 10 141 peptides per
well were incubated for 16 h at room temperature and washed twice
with 0.1% BSA in PBS. Unoccupied sites were saturated with 1%
BSA in PBS for 1 h . The plates were washed three times and radio-
labeled HLA molecules were added and placed at room tempera-
ture for 18 h . The plates were then washed three times and radio-
activity bound per well was measured by direct counting in agamma
counter.
Detection ofHLA by mAbs .
￿
HLA molecules bound on peptide-
precoated plates were detected by anti-HLAmAb and radiolabeled
rabbit anti-mouse antibodies as secondary and tertiary reagents.
HLA molecules were added to peptide precoated plates for 18 h
at room temperature then washed three times with 0.1% BSA in
PBS followed byincubation with 1% ovalbumin in PBS for 30 min
1 . Al 60-84 WDQETRDMKAHSQTDRANLGTLRGY 33 . B13 60-84 WDRETQISKTNTQTYRENLRTALRY
2 . A2 98-113 MYGCDVGSDWRFLRGY 34 . B14 60-84 WDRNTQICKTNTQTDRETLRNLRGY
3 . A2 56-69 GPEYWDGETRKVKA 35 . B41 60-84 WDRETQISKTNTQTYRESLRNLRGY
4 . A2 57-69 -PEYWDGETRKVKA 36 . B42 60-84 WDRNTQIYKAQAQTDRESLRNLRGY
5 . A2 58-69 --EYWDGETRKVKA 37 . B44 .1 60-84 WDRETQISKTNTQTYRENLRTAARY
6 . A2 59-69 ---YWDGETRKVKA 38 . 844 .1 141-160 QITQRKWEAARVAEQDRAYL
7 . A2 60-69 ----WDGETRKVKA 39 . B47 60-84 WDRETQISKTNTQTYREDLRTLLRY
8 . A2 61-69 -----DGETRKVKA 40 . Cwl 60-84 WDRNTQIYKAQAQTDRESLRNLRGY
9 . A2 62-69 ------GETRKVKA 41 . Cw2 .1 60-84 WDRETQKYKRQAQTDRVNLRKLRGY
10 . A2 60-84 WDGETRKVKAHSQTHRVDLGTLRGY 42 . Cw3 60-84 WDRNTQIYKAQAQTDRESLRNLRGY
11 . A2 70-85 HSQTHRVDLGTLRGYY 43 . 82M 1-16 IQRTPKIQVYSRHPAE
12 . A2 87-102 QSEAGSHTVQRMYGCD 44 . 32M a-25 QVYSRHPAENGKSNFLNC
13 . A2 112-129 KDYIALKEDLRSWTA 45 . f32m 25-41 CYVSGFHPSDIEVDLLK
14 . A2 141-160 QTTKHKWEAAHVAEQLRAYL 46 . 82M 38-54 DLLKNGERIEKVEHSD
15 . A2 161-171 GTCVEWLRRY 47 . BZm 51-66 HSDLSFSKDWSFYLLY
16 . A2 146-161 KWEAAHVAEQLRAYLE 48 . 82M 67-79 YTEFTPTEKDEYA
17 . A2 137-148 DMAAQTTKHKWE 49 . J3 2M 80-94 CRVNHVTLSQPKIVK
18 . A2 266-282 LPKPLTLRWEPSSQPTI 50 . Bzm 83-99 NHVTLSQPKIVKWDRDM
19 . Aw24 60-84 WDEETGKVKAHSQTDRENLRIALRY 51 . FLU M57-68 KGILGFVFTLTV
20 . A32 60-84 WDQETRNVKAHSQTDRESLRIALRY 52 . LMP VMSDWTGGALLC
21 . Aw68 .1 141-160 QTTKHKWEAAHVAEQWRAYL 53 . HIV .gag 265-279 KRWILGLNKIVRMYC
22 . Aw68 .1 98-113 MYGCDVGSDGRFLRG 54 . FLU.NP335-349 SAAFEDLRVLSFIRG
23 . Aw68 .1 60-84 WDRNTRNVKAQSQTDRVDLGTLRGY 55 . LCa 47-71 FAILDGGAPGPQPHGEPPGGPDAVD
56 . LCa 113-137 MERLEALDANSRKQEAEWKEKAIKE 24 . Aw68 .1 56-69 GPEYWDRNTRNVKA
57 . LCa 148-164 QLQKTKANNRAAEEAFV
25 . Aw68 .1 70-85 QSQTDRVDLGTLRGYY
58 . LCa 188-208 AAEEAFVNDIEESSPGTEWER
26 . Aw68 .1 87-102 QSEAGSHTIQRMYGCD
59 . LCa 204-226 TEWERVARLCDFNPKSSKQAKDV
27 . Bw58 56-69 GPEYWDGETRNMKA
60 . LCb 45-72 EGFGAPAGSHAAPAQPGPTSGAGSEDMG
28 . Bw58 60-84 WDGETRNMKASAQTYRENLRIALRY
61 . LCb 113-135 RKRLQELDAASKVTEQEWAEKAK
29 . B7 60-84 WDRNTQIYKAQAQTDRESLRNLRGY
62 . LCb 148-164 QVEKNKINNRASEEAFV
30 . B27 .1 60-84 WDRETQICKAKAQTDREDLRTLLRY
63 . LCb 188-208 ASEEAFVKESKEETPGTEWEK
31 . B27 .2 60-84 WDRETQICKAKAQTDRENLRIALRY 64 . LCb 208-229 KVAQLCDFNPKSSKQCKDVSRL
32 . B27 .3 60-84 WDRETQICKAKAQTDRESLRTLLRY5
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at 4°C. After incubation, the microwells were washed twice and
anti-HLA mAbs (250 jig/ml) were added to each well andplaced
at 4°Cfor45 min. At that time, themicrowells were then washed
three times with 0.1% BSA in PBS and radioiodinated rabbit
anti-mouse F(ab')2 were addedto each well at 600,000cpm/well.
Theplates were placed at 4°Cfor45 min, then washed three times
and radioactivity bound per well was counted.
Comparison of the crystallographic structures ofHLAA2.1
and HLAAw68.1 revealed differences in the detailed architec-
25 50 75 100
64 .4.
B44
150
￿
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Figure 2.
￿
Direct binding of HLA
molecules to peptides. Peptides were
coated onto polystyrene microwells
in duplicate at 10 Ag/well and were
placed at room temperature for 16 h
before saturating the unbound sites
with 1% BSA in PBS. HLA mole-
cules radioiodinated by the chlora-
mine T method were diluted in
PBS containing 0.5% NP-40, 1%
BSA, 0.02% NaN3, and 1 mM
PMSF and 10 ng was added to each
microwell. The reaction plates were
placed at room temperature for 18 h
then washed three times with 0.1%
BSA and 0.5% NP-40 in PBS, air
dried, and radioactivity bound per
well was counted. (A) Peptides of
viral, HLA, and clathrin proteins.
(B) Analogues of influenza matrix
peptide F1u.M57-68.
5
0
ture of the peptide binding groove, indicating that these mol-
ecules would exhibit distinctive peptide binding specificity
(5). In an attempt to identify discriminating peptides we tested
64 peptides for binding to HLAA2.1 and HLAAw68.1 using
the solid-phase assay ofBouillot et al. (12). Binding to HLA
Aw69, which has a hybrid peptide binding groove (at de-
rived from HLAAw68.1 and (X2 derived from HLAA2.1)
and to HLAB44 and HLAB5 was also assessed. The pep-
tidestested had sequences derived from various viral antigens,
HLAA,B,C heavy and light chains and clathrin light chains
(Fig. 1).
A A2.1 Aw69 Aw68.1 B5 B44ul domain
1 10 20 30 40 50 60 70 80 90
consensus GSHSMRYFYTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASPRMEPRAPWIEQEGPEYWDRETQIVKAQSQTDRESLRTLRGYYNQSEA
A2 .1 --------F---------------------------------Q------------------G-_RK---H---H-VD-G-------__--
Aw69 ------------------------------------------Q-------------------N-RN-__--__--VD-G-------__--
Aw68 .1 ---__--__---------------------------------Q-------------------N-RN---------VD-G-----------
B44 .2 ----------AN-----------T-------L--------T---K---------------------S-TNT--Y--N---ALR-------
B51 ----------AM--------------------------------T-----------------N---F-TNT--Y--N--IALR-------
consensus GSNSMRYFYTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASPRMEPRAPWIEQEGPEYWDRETQIVKAQSQTDRESLRTLRGYYNQSEA
1 10 20 30 40 50 60 70 80 90
o2 domain
100 110 120 130 140 150 160 170 180
consensus GSHTLQRMYGCDVGPDGRLLRGYHQYAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAARVAEQLRAYLEGTCVEWLRRYLENGKETLQRA
A2 .1 ----V---------S-W-F-----------------K----------M---T-KH-----H--__--------------------------T
Aw69 ----V---------S-W-F-----------------K----------M---T-KH-----H------------------------------T
Aw68 .1 ----I-M-------S---F----R-D----------K----------M---T-KH-----H----W-------------------------T
B44 .2 ---II------------------D-D--------------S------------------------D--__--L---S---------------
B51 ---II-----------------HN----------------S--------------------E----------L-------H-----------
consensus GSHTLQRMYGCDVGPDGRLLRGYHQYAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAARVAEQLRAYLEGTCVEWLRRYLENGKETLQRA
100 110 120 130 140 150 160 170 180
0 domain
190 200 210 220 230 240 250 260 270
consensus DPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRW
A2 .1 -A----M---AV------------S-------------------------------G-------------Q---------------------
Aw69 -A----M---AV------------S-------------------------------G-------------Q-------------__------
Aw68 .1 -A----M---AV------------S-------------------------------G-----V-------Q---------------------
B44.2 ----------------V---------------------------------------------------------------------------
B51 -----------V--------------------------------------------------------------------------------
consensus DPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRW
190 200 210 220 230 240 250 260 270
Fifteen of the 64 peptides bound to HLAA2.1 at levels
>10-fold of background, 15 peptides gave binding twofold
above background levels and 34 were negative '(Fig. 2 A) .
Positively binding peptides were foundamong the HLA pep-
tides and the viral peptides, but not among the clathrin pep-
tides . The lack ofHLA binding to the clathrin peptides was
not due to poor absorption ofpeptides to the microtiter plates
as many of these peptides bind to specific anti-clathrin mono-
clonal and polyclonal antibodies in similarly configured assays
(14) . Thus, there is, as previously demonstrated (12), discrimi-
nation between peptides in this assay . Calculation also shows
that up to 30% of the total input of radio-iodinated HLA-
A2.1 molecules can bind to solid-phase peptide . Among the
strongly binding peptides is that corresponding to residues
57-68 of the influenza matrix peptide (F1u.M57-68) and the
binding of HLA-A2.1 to this peptide we observed is com-
parable to that reported by Bouillot et al. (12) . This peptide
has repeatedly beenshown to be presented to influenza specific
CTL byHLAA2.1 andHLAAw69 (15) . In addition, Gotch
et al . (16) have tested peptide analogues for their capacity
to substitute for F1u.M57-68 and have identified positions
at which substitution prevents presentation to specific CTL .
The pattern of binding ofHLAA2.1 to these analogue pep-
tides observed in the solid-phase assay closely correlates with
the pattern of sensitization observed by Gotch and colleagues
(Gotch, A, and McMichael, A . J ., unpublished data, personal
communication), showing that among this highly related set
of peptides, binding correlates with presentation (Fig. 2 B)
with the exception that peptides E63, Y63, and F63 bound
in the solid-phase assay and were not recognized byCTL and
did not inhibit presentation of the matrix peptidebyHLAA2 .
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Figure 3 .
￿
The amino acid se-
quences of the al, a2, and a3
domains of the five HLA-A and
-B molecules studied here. The
standard one-letter amino acid
code is used . A dash indicates
that a residue is identical to that
found in the consensus sequence.
It was therefore surprising that no significant discrimina-
tion between five differentMHC molecules was observed in
this binding assay ; the pattern of binding of HLAA2.1 to
the 64 peptides was mimicked byHLAAw68.1, Aw69, B5,
andB44 (Fig. 2) . Thus every peptide thatbound to one HLA
molecule bound to the other four; peptides that failed to bind
to one HLA molecule did not bind to the other four. Even
when the levels of binding of different peptides to the five
HLA molecules were compared, there were no significant
differences that could be ascribed to "HLA type."
These results clearly challenge the hypothesis that varia-
tion between class IMHC molecules, which is mainly found
in the peptide binding groove, acts significantly to alter the
peptide binding specificity. The five HLAA,B molecules
studied here show considerable variation in the residues that
point into the groove, between 5 and 17 amino acid differ-
ences (Fig . 3), and yet their pattern of peptide binding ap-
pears identical .
This raised the possibility that it was denaturedHLA mol-
ecules, or an iodinated contaminant in theHLA preparations,
that was binding the peptides. To address this question we
separated radio-iodinatedHLAA2 on a column of a W6/32,
a mAb that only binds to native Dam-associated molecules,
and measured the binding to peptides of the bound and the
unbound radioactivity. All peptide binding activity of the
1251-HLAA2 preparation was removed by passage over the
W6/32 column, showing that the observed peptide binding
was due to 02m-associated HLAA2 heavy chains and not to
free heavy chains or a contaminant . This conclusion was
confirmed by the recovery ofpeptide binding activity by elu-
tion of material bound to the W6/32 column . Moreover,Table 1.
￿
Binding of Peptides by Radioiodinated HLA-A2 .1
Molecules Reisolated by Affinity Chromatography
Amount of radioactivity added to each well .
t Amount of radioactivity bound to each well after three washes to
remove excess radioactivity .
only a fraction (1/10) of the radioactivity was needed to achieve
binding comparable to the level obtained with unfractionated
radiolabeled HLAA2 (Table 1) .
A further source of potential artefact is modification of
the HLA molecules by the iodination reaction . The peptide
binding groove of MHC molecules is characterized by a
number of strategically placed tyrosine residues (4) and it is
possible that their iodination could alter the combining site
specificity to give a degenerate pattern of peptide binding.
Neg . control
A2.57-69
A2.98-113
FIu.NP.335-349
HIV.gag.265-279
FIu.M57-68
p2M.51-66
847.60-84
844.141-160
841 .60-84
813.60-84
827 .3.60-84
827 .2.60-84
Bw58 .60-84
Aw68.141-160
A32.60.84
Aw24.60.84
A2.60-84
S B47:8084
844.141-160
841.80-84
N Control
.98-113
FIUAR335-349
HIV .gep 285-279
FfU.M57-86
813.60-84
827.3.60-84
827.2.60-84
Aw68141-180
A32.60.84
Aw24.50 .84
A2.60-84
W6/32
C
L
0 10 20 30 10 20
125 1 bound x10 -3 c.p.m .
Aw69
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Aw68.1
MA2 .1
0 10 20 30 40 10 20 30 40 10 20 30 40 10
125 1 bound x10 -3 C .P.M .
To circumvent this issue we developed a modified assay in
which the binding of noniodinatedHLA molecules to plate-
bound peptides was measured using specific anti-HLAA,B
mousemAbs and radiciodinated anti-mouse Ig (Fig. 4) . This
indirect assay gave similar patterns ofpeptide binding to those
seen in the direct assay and equivalent results were obtained
with sixmAbs directed against different epitopes ofHLAA,B
molecules ; results obtained with W6/32 and A2.1 mAb are
shown (Fig. 4A) . Protein modification due to radio-iodination
is therefore not the source of the degenerate binding .
Discussion
Bouillet et al . (12) previously analyzed the binding ofradio-
iodinatedHLAA2.1,HLA1137, and HLAB27 to solid-phase
peptides . Peptides that were known to be antigenic for T
cells bound to their appropriate restriction element, but al-
though some quantitative differences were observed, these
authors found that peptides binding to one class I molecule
tended to bind to others. In three cases where direct compar-
ison can be made, the binding ofHLAA2.1 to influenza nu-
clear protein peptideFLU.NP335-349, influenza matrix pro-
tein peptide FLU.M57-68, and HIV gag protein peptide
HIVgag.265-279, we obtain comparable results to Bouillot
et al. Furthermore we find the assay robust, highly repro-
ducible, and suitable for screening large numbers of samples .
Comparison of the binding of the same MHC molecule
to different peptides showed specificity that correlated with
Figure 4.
￿
Binding of HLA mole-
cules to peptides detected by an in-
direct binding assay. HLA prepara-
tions were added to microwells
30
￿
10
￿
20
￿
30
￿
precoated with peptides and presatu-
rated with 1% BSA . The reaction
plates were placed at room tempera-
ture for 18 h then washed three
times, and unbound sites were satu-
rated with 1% ovalbumin in PBS .
Monomorphic anti-HLA antibody
W6/32. at 250 leg/ml was added to
each well in 50 ul and incubated at
4°C for 45 min . : The microwells
were washed three times and 1251-
labeled rabbit anti-mouse F(ab')2
were added to each well for an ad-
ditional 45 mina Radioactivity
bound per well was measured by di-
rect counting of well washed to re-
move excess radioactivity.
887 .1
844
20 30 40 10 20 30 40
Binding by fractions of HLA-A2.1 preparation
Pre W6/32 column Eluate Run through
Peptides 600,000' 50,000 50,000 50,000
FLU.M57-68 7,640# 1,234 6,585 638
Bw58.60-84 11,347 1,876 13,856 1,214
B41.60-84 15,867 2,413 15,888 1,070
None 1,812 1,180 1,593 440presentation to T cells. In contrast we found no significant
differences in the patterns ofpeptide binding of five different
class I molecules. Bouillot et al. were able to discern some
quantitative differences in titration experiments. In this study
peptides were plated at 1 mg/ml, a concentration that for
known antigens gave maximal binding, and this protocol may
have served to reduce the discriminating capacity of the assay.
Nevertheless it is clearfrom our results and those ofFrelinger
et al. (17) with this assay that it is hard to argue for a pro-
found effect of MHC polymorphism on the binding ofpep-
tides to HLAA,B molecules. The critical issue is whether
this is a true reflection of the specificity of peptide binding
by class I molecules or an artefact of the assay.
Trivial artefacts have been ruled out. The binding is clearly
the product of 02m-associated HLAA,B heavy chains and
is not dependent upon radioiodination. Conformational an-
tigenic determinants of the HLAA,B molecules are preserved
on binding to solid-phase peptides. In addition we know that
binding does not require the presence ofdetergent or the hy-
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drophobic transmembrane region of the HLAA,B molecule.
Papain solubilized and genetically engineered, secreted HLA
molecules give similar binding to the detergent solubilized
product.
These results combined with the peptide specificity and
its correlation with T cell reactivity argue for binding being
within the peptide binding groove. That the binding grooves
of a much greater proportionof HLAA,B molecules are ac-
cessible to solid-phase peptides than to peptides in solution
suggests that interactions at the solid phase facilitate either
displacement of the endogenous peptide or the simultaneous
binding of the endogenous peptide and the experimentally
offered peptide. This might involve nonphysiological inter-
actions between the class I molecules and plastic that loosen
up the structure and thereby reduce the specificity ofthe com-
bining site. Alternatively the plastic surface might mimic con-
ditions that MHC molecules encounter in vivo and which
contribute to their function.
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